Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort

ObjectivesImmunotherapy plus chemotherapy has recently been applied in the neoadjuvant treatment for locally advanced gastric cancer (LAGC), while its superiority over neoadjuvant chemotherapy (NACT) alone remains to be explored. This study explored the safety and efficacy of NACT plus tislelizumab...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Qi Jiang, Weizhen Liu, Xiangyu Zeng, Chenggang Zhang, Yuqiang Du, Liwu Zeng, Yuping Yin, Jun Fan, Ming Yang, Kaixiong Tao, Peng Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-05-01
Edice:	Frontiers in Immunology
Témata:	neoadjuvant chemotherapy gastric cancer tislelizumab gastrectomy efficacy
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1122121/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!